Phase 4 N=9 Randomized Triple-blind Treatment

Cognitive Decline in Non-demented PD

Parkinson's Disease

Bottom Line

View on ClinicalTrials.gov: NCT01340885 ↗

Enrolled (actual)

Serious AEs

—

Results posted

Jul 2020

Primary outcome: Primary: Attention Network Effects

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Strattera (Drug); Exelon (Drug); Placebo (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Oregon Health and Science University
Primary completion: Jan 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY Attention Network Effects	—	—
SECONDARY Quality of Life	—	—
SECONDARY Stroop Color Word Test	—	—
SECONDARY Fatigue	—	—
SECONDARY Depression	—	—
SECONDARY Daytime Sleepiness	—	—

Summary

The purpose of this study is to determine the relationship between attention and quality of life and how rivastigmine and atomoxetine alter attention in non-demented persons with Parkinson's disease (PD).

Eligibility Criteria

Inclusion Criteria

Clinical diagnosis of Parkinson's disease
Respond to levodopa therapy

Exclusion Criteria

Dementia
Psychiatric disorders including anxiety disorders, dissociative disorders, mood disorders, schizophrenia and related disorders, or ADD/ADHD
Any clinically unstable disease such as cancer, HIV/AIDS, heart condition, liver disease, kidney or renal failure or others that might require hospitalization
Evidence for another neurological disease (history of seizures, Alzheimer disease, multiple sclerosis or other movement disorders);
Currently using any of the study drugs;
Colorblindness

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01340885). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.